In this section
@article{Allegretti:2019:10.1016/S0140-6736(19)31266-8,
author = {Allegretti, JR and Mullish, BH and Kelly, C and Fischer, M},
doi = {10.1016/S0140-6736(19)31266-8},
journal = {Lancet},
pages = {420--431},
title = {The evolution of the use of faecal microbiota transplantation and emerging therapeutic indications.},
url = {http://dx.doi.org/10.1016/S0140-6736(19)31266-8},
volume = {394},
year = {2019}
}
TY - JOUR
AB - Developments in high-throughput microbial genomic sequencing and other systems biology techniques have given novel insight into the potential contribution of the gut microbiota to health and disease. As a result, an increasing number of diseases have been characterised by distinctive changes in the composition and functionality of the gut microbiota; however, whether such changes are cause, consequence, or incidental to the disease in question remains largely uncertain. Restoration of the gut microbiota to a premorbid state is a key novel therapeutic approach of interest, and faecal microbiota transplantation-the transfer of prescreened stool from healthy donors into the gastrointestinal tract of patients-is gaining increasing importance in both the clinical and research settings. At present, faecal microbiota transplantation is only recommended in the treatment of recurrent Clostridioides difficile infection, although a large number of trials are ongoing worldwide exploring other potential therapeutic indications.
AU - Allegretti,JR
AU - Mullish,BH
AU - Kelly,C
AU - Fischer,M
DO - 10.1016/S0140-6736(19)31266-8
EP - 431
PY - 2019///
SP - 420
TI - The evolution of the use of faecal microbiota transplantation and emerging therapeutic indications.
T2 - Lancet
UR - http://dx.doi.org/10.1016/S0140-6736(19)31266-8
UR - https://www.ncbi.nlm.nih.gov/pubmed/31379333
UR - http://hdl.handle.net/10044/1/70605
VL - 394
ER -
For any enquiries about the Microbiome Network at Imperial, please contact: